Showing results (241-250 of 286) with videos related to
Sort By:
Pageof 29
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2007
A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group studyBrenda J Weigel, Susan M Blaney, Joel M Reid, et al.The Lancet. Oncology|April 20, 2013
Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium studyYael P Mossé, Megan S Lim, Stephan D Voss, et al.Journal of Clinical Immunology|January 1, 2022
Prevalence of Pathogenic and Potentially Pathogenic Inborn Error of Immunity Associated Variants in Children with Severe SepsisKate F Kernan, Lina Ghaloul-Gonzalez, Jerry Vockley, et al.JAMA Network Open|May 27, 2021
Personal and Professional Factors Associated With Work-Life Integration Among US PhysiciansDaniel S Tawfik, Tait D Shanafelt, Liselotte N Dyrbye, et al.Pediatric Blood & Cancer|December 19, 2013
Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: a report from the Children's Oncology Group (ANBL0621)Elizabeth Fox, Yael P Mosse', Holly M Meany, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 18, 2006
A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumorsElizabeth Fox, John M Maris, Brigitte C Widemann, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2011
Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology GroupSuman Malempati, Brenda Weigel, Ashish M Ingle, et al.The European Respiratory Journal|October 3, 2020
Temporal airway microbiome changes related to ventilator-associated pneumonia in childrenPeter M Mourani, Marci K Sontag, Kayla M Williamson, et al.Medrxiv : the Preprint Server for Health Sciences|July 1, 2024
Dysregulated STAT3 signaling and T cell immunometabolic dysfunction define a targetable, high mortality subphenotype of critically ill childrenRobert B Lindell, Samir Sayed, Jose S Campos, et al.Pediatric Blood & Cancer|May 7, 2015
Comparison of in-patient costs for children treated on the AAML0531 clinical trial: A report from the Children's Oncology GroupKelly D Getz, Yimei Li, Todd A Alonzo, et al.Pageof 29